ReviewJournal of gastrointestinal cancer2021
Targeting the Mevalonate Pathway for Treating Esophageal Cancer.
Review in Journal of gastrointestinal cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Arteannuin B Induces Ferroptosis in Colorectal Cancer Cells via GDF15/HMGCS1/GPX4 Axis.Journal of Cancer · 2026Article
- Unveiling the potential benefits of statins in medulloblastoma treatment: A promising therapeutic approach.IBRO neuroscience reports · 2025Review
- Obesity Affects IVF Outcomes and Mevalonic Acid Rescues the Side Effects of Statins on Follicle Growth.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo asseess whether the mevalonate pathway can be targeted in managing patients with esophageal cancer.
methodsThis a narrative review of peer-revieweed publications indexed in MedLine PubMed. The search was conducted by using "Esophageal cancer", "Mevalonate pahtway", "Statins", and "Translational research."
resultsThe mevalonate pathway is an important metabolic pathway that is involved in various cellular functions. Its downstream products are essential for cell-signaling, cell membrane integrity, protein synthesis, and cellular respiration. Statins, a class of medications that are best known as lipid-lowering drugs, inhibit the rate-limiting enzyme of this pathway. Many studies have shown that a variety of cancerous cells have a dysregulated mevalonate pathway. Esophageal cancer is a malignancy that has a poor prognosis, which is mainly due to patients presenting once the cancer is in the advances stages. Chemotherapy has been the mainstay for treating esophageal cancer. However, these agents are not consistently effective and fail to differentiate between the different subtypes of esophageal cancers. Identifying other classes of drugs which could possess anti esophageal cancer properties is appealing.
conclusionThere is a growing body of literature that has shown the anti-cancer properties of statins in the setting of various malignancies. Herein, we summarize the current literature as it pertains to how the mevalonate pathway can be targeted by statins for potentially treating esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.